ArticleAesthetic surgery journal2025
Histomorphologic Outcomes of GalaFLEX Scaffold Used in Breast Surgery: Clinical Follow-up From 6 Weeks to 63 Months.
Article in Aesthetic surgery journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Clinical Characteristics and Use of Poly-4-Hydroxybutyrate Scaffold (GalaFLEX™) in Primary and Secondary Implant-Based Breast Reconstruction: A Structured Review of the Literature and Preliminary Single-Center Experience.Aesthetic plastic surgery · 2026Article
- Tissue response to the use of synthetic and biological meshes in implant-based breast surgery: A histomorphological case-series of six patients.JPRAS open · 2026Article
- Clinical Performance of GalaFLEX® (Poly-4-Hydroxybutyrate) Scaffold Application in Aesthetic and Reconstructive Breast Surgery: A Retrospective Study.Aesthetic plastic surgery · 2026Article
- Soft Tissue Scaffolds in Breast Reconstruction: Evolution from Acellular Dermal Matrices to Synthetic Polymers.Journal of clinical medicine · 2026Review
- 4-Hydroxybutyrate (4HB) released from poly-4-hydroxybutyrate scaffolds does not impact hallmark phenotypes of cancer in malignant or non-malignant breast cells.Breast cancer research : BCR · 2026Article
- Early Performance of a Multifilament Resorbable Synthetic Mesh in Aesthetic Breast Surgery: A 206 Patient Experience.Aesthetic surgery journal. Open forum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe use of scaffolds in reconstructive and aesthetic breast surgeries for soft tissue reinforcement has increased over time. However, histomorphologic outcomes with the use of such materials are not typically reported. The present study describes the histologic findings associated with the use of the GalaFLEX Scaffold by BD (Franklin Lakes, NJ), an absorbable biosynthetic material, when used as soft tissue support in breast surgery.
objectivesThe present study evaluates the histomorphologic patterns of a 10-patient cohort that received GalaFLEX Scaffolds as soft tissue support in breast surgery, with and without breast implants.
methodsTissue biopsy specimens that included the implanted GalaFLEX Scaffold were collected during revision from 6 weeks to 63 months postimplantation. General staining and specific immunolabeling were used to determine cellular infiltration, tissue composition and organization, and vascularization.
resultsBiopsy specimens showed slow degradation of the GalaFLEX Scaffold, robust vascularization, mononuclear cell infiltration that decreased with time, and deposition of an organized collagenous connective tissue matrix in the interfiber space of the GalaFLEX Scaffold. There was no evidence for chronic inflammation or a foreign body response. The pattern of tissue remodeling around and within the fibers suggests a constructive tissue remodeling process rather than the formation of dense capsular tissue with contraction.
conclusionsImplantation of the GalaFLEX Scaffold for reconstructive and cosmetic breast surgery appears to be safe and is associated with slow scaffold degradation, neovascularization, and mononuclear cell infiltration that diminishes with time, and a constructive remodeling response devoid of chronic inflammation or foreign body response. These conclusions are limited by the size of the 10-patient cohort. LEVEL OF EVIDENCE: 4 (THERAPEUTIC):
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.